在高血压患者中进行初步,随机,双盲,安慰剂控制的交叉研究
Ebrahim Shafiei1, Mikaeil Rezaei1, Marzieh Mahmoodi2
1Bushehr Heart Center, affiliated with Bushehr University of Medical Sciences, Bushehr, Iran.
Scientific reports
|August 25, 2025
概括
在患有前高血压或第一阶段高血压的患者中,复星补充剂增加了氧化 (NO),但没有显著降低血压. 需要进一步的长期研究来证实这些初步发现.
科学领域:
- 心血管医学
- 药理学
- 营养药物
背景情况:
- 高血压是一个全球性的健康问题,需要新的治疗策略.
- 植物衍生化合物如白醇正在研究其潜在的健康益处.
- 复星是一种多, 已显示出抗氧化和抗炎性质.
研究的目的:
- 评估白醇在高血压前和第一阶段高血压患者的治疗效果.
- 评估复星补充剂对静脉压和静脉压的影响.
- 探索白醇对氧化 (NO) 水平的影响.
主要方法:
- 进行了一项随机,交叉,双盲,安慰剂对照的试验.
- 参与者每天两次服用500毫克白醇或安慰剂,持续4周,然后进行4周的清洗期,然后切换治疗.
- 每周对血压进行监测,并测量氧化水平.
主要成果:
- 与安慰剂相比,复星补充剂没有导致缩或腹缩血压显著降低.
- 在接受白醇治疗的组中,氧化 (NO) 含量明显高于安慰剂组.
- 该研究没有发现白醇和安慰剂之间的血压降低效果有显著差异.
结论:
- 在患有高血压前期或第一阶段高血压的患者中,短期补充白醇可增强氧化的产生,但不能显著降低血压.
- 这些发现是初步的,需要通过更大规模的长期临床试验进行验证.
- 在这种人群中,除了直接降低血压之外,resveratrol可能会通过其他机制影响心血管健康.
相关概念视频
Hypertension III: Clinical Manifestations and Diagnostic Studies
48
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
48
Hypertension and Regulation of Blood Pressure
3.1K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
3.1K
Atherosclerosis III: Management
33
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33
Hypertension IV: Drug Therapy and Lifestyle Modifications
38
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
38
Hypertension II: Pathophysiology
77
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
77
Blind Procedures
12.1K
Ideally, the people who observe and record the children’s behavior are unaware of who was assigned to the experimental or control group, in order to control for experimenter bias. Experimenter bias refers to the possibility that a researcher’s expectations might skew the results of the study. Remember, conducting an experiment requires a lot of planning, and the people involved in the research project have a vested interest in supporting their hypotheses. If the observers knew which...
12.1K


